... to in the content or advertisements. 2023 Tumor lysis syndrome Non-small cell lung cancer Pulmonary adenocarcinoma Spontaneous lysis Case report Tumor lysis syndrome (TLS) is a syndrome characterized by several clinical and laboratory findings due to the release into the circulation of large...

..., instructions or products referred to in the content or advertisements. 2023 Multiple primary malignancy Osimertinib Chemotherapy Epidermal growth factor receptor Non-small cell lung cancer Breast cancer Multiple synchronous primary malignancies largely refer to the co-occurrence of two...

...Lorenz Frehner; Simon Haefliger; Ferdinando Cerciello; Tobias Grob; Sabine Schmid In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however...

...Caroline Esmonde-White; David Palma; Adam Mutsaers A 62-year-old woman with a 40-pack-year smoking history and severe chronic obstructive pulmonary disease with early-stage right upper lobe non-small cell lung cancer (NSCLC) was treated with stereotactic ablative radiotherapy (SABR). Two years...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 EGFR-TKI Lung cancer Non-small cell lung cancer Transient asymptomatic pulmonary opacity Epidermal growth factor receptor (EGFR)-TKI is the key drug for EGFR...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Docetaxel Atezolizumab Edema Non-small cell lung cancer Prostate cancer...

... of pembrolizumab, which is a humanized monoclonal anti-programmed cell death-1 (anti-PD1) IgG4 antibody that targets tumours expressing PDL-1. In our case, this monoclonal antibody (MAB) was being used for the treatment of metastatic non-small cell lung cancer, before being withheld because of this potentially...

... interstitial pneumonitis is one of the irAEs, and its incidence is reported as 3.5–8.3% in phase III trials of nivolumab with or without ipilimumab for advanced non-small cell lung cancer patients. However, in the real-world setting, pathology is not routinely used in the diagnostic process of interstitial...

... cancer Metastasis Non-small cell lung cancer Recurrence Adverse effects Tyrosine-kinase inhibitor ROS proto-oncogene 1 (ROS1) fusion-positive lung adenocarcinoma, first identified in 2007 and further established in 2012, is a rare type of lung cancer accounting for approximately 1% of all...

...Philippa Kate Harrison; Helen E Boland; Noel J Aherne; David J Palmieri The discovery of tyrosine kinase oncogenic driver mutations, including anaplastic lymphoma kinase (ALK), has changed the face of non-small cell lung cancer (NSCLC) treatment. Whilst the development of tyrosine kinase inhibitors...

..., instructions or products referred to in the content or advertisements. Thrombotic microangiopathy Non-small cell lung cancer Gemcitabine Autopsy Plasmapheresis Gemcitabine is a pyrimidine antimetabolite that acts against solid tumors and has been shown to be effective against non-small cell...

... in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized...

.... Epidermal growth factor receptor mutation Gefitinib Erlotinib Non-small cell lung cancer Mechanisms of resistance Patients with epidermal growth factor receptor ( EGFR )-mutant lung cancer develop acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) within a year [1-3], despite...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Immune checkpoint inhibitor Non-small cell lung cancer Pathological complete response Pembrolizumab Pulmonary hypertrophic osteoarthropathy Lung cancer...

... indications in previously untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR or ALK mutations. In the majority of cases, the presence of the ALK rearrangement mutation does not overlap with other mutations in NSCLC. Here, we report a patient with concomitant ALK rearrangement and EGFR...

..., supervised care of the patient, and provided critical inputs for the final manuscript. References 1. Soria   JC , Ohe   Y , Vansteenkiste   J , Reungwetwattana   T , Chewaskulyong   B , Lee   KH ,   Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer . N...

.... Non-small cell lung cancer EGFR mutation MET amplification Targeted therapy Epidermal growth factor receptor ( EGFR ) mutations are detected in approximately 10–15% of non-small cell lung cancers (NSCLCs), and exon 19 deletion and exon 21 p.L858R mutations account for 85–90...

.... Non-small cell lung cancer Diffuse cysts Immune checkpoint inhibitor Radiology Diagnosis Diffuse cysts in the lung can be found in many diseases, but rarely in metastatic lung adenocarcinoma [ 1 ]. The presence of diffuse cysts after the administration of immune checkpoint inhibitors...

... with lung cancer. The frequency of brain metastasis and carcinomatous meningitis during the entire clinical course of non-small cell lung cancer is reported to be about 40% and 5%, respectively. In contrast, the incidence of cranial nerve metastasis is extremely rare, and detailed reports of its clinical...

... with leptomeningeal disease at diagnosis. In this case, the presence of leptomeningeal carcinomatosis at diagnosis, not as a late manifestation of heavily pretreated disease, alludes to a possible association between leptomeningeal involvement and BRAF-mutated non-small cell lung cancer. bailey.fitz@gmail.com...